Manipal Health Enterprises IPO

Manipal Health Enterprises Limited is a listed issue, offered in a price band of ₹590 to ₹590 per share, in lots of 25 shares. Every figure below is taken from the issue's own filings and exchange disclosures.

Issue details

Price band

₹590 – ₹590

Lot size

25 shares

Minimum investment

₹14,750

Issue size

₹9,705.54 Cr

Fresh issue

₹8,000 Cr

Offer for sale

₹1,275.21 Cr

Opens

29 Jul 2026

Closes

31 Jul 2026

Listing date

5 Aug 2026

Registrar

KFin Technologies Limited

Symbol

MANIPALHOS

One lot of 25 shares at the upper band price of ₹590 is ₹14,750 — the smallest retail application this issue accepts.

Lead managers: Kotak Mahindra Capital Company Limited.

Subscription status

How many times the issue has been applied for, by investor category, as reported by the exchange at 31 Jul 2026, 07:05 pm IST.

Grey market premium (GMP)

Latest reported GMP

₹3

Implied over upper band

0.50%

As of

5 Aug 2026, 07:05 pm IST

How the reported premium has moved. The trend matters more than any single reading — a premium that is drifting down into the close is a different signal from one holding firm.

Grey Market Premium is an unofficial, unregulated over-the-counter datapoint reported by third parties. It is not a price, a forecast, or an indication of listing gains, and is not investment advice.

Reported financials

As disclosed in the offer document. Figures in ₹ crore unless the filing states otherwise.

Strengths disclosed in the offer document

• The company is India's largest multispecialty hospital group by bed capacity with a pan-India presence.
• The company has the widest footprint in terms of presence of hospitals among private hospital chains in India.
• The company operates a patient-centric ecosystem rooted in transparency, and clinical and service excellence.
• The company focuses on reducing turn-around-times (TATs), adopts digital tools, and provides culturally sensitive multi-lingual support.
• The company's brand, breadth of specialties, academic programs, and integrated network make it an attractive workplace for healthcare professionals.
• The company provides an enabling environment for clinical advancement to doctors by offering access to advanced medical technologies and infrastructure and regular knowledge exchange.
• The company routinely performs advanced interventions and complex procedures including structural heart and minimally invasive cardiac surgery.
• The company has a repeatable playbook for integrating and scaling transformative acquisitions to improve access to quality healthcare.

Risk factors disclosed in the offer document

• The company's revenue from operations is derived substantially from Karnataka, and any loss of business or disruption in operations in Karnataka could have a material adverse effect.
• The company primarily generates revenue by providing inpatient care at its hospitals, and any inability to maintain or improve its admissions and hospital occupancy rates could adversely affect its business.
• The company derives a significant portion of its revenue from the CONGO-R specialties, and any negative changes in the demand for these specialties could adversely impact its business.
• The company's reliance on third-party suppliers and subcontractors for supplies, equipment, housekeeping and security services could have a material adverse impact on its business.
• The company is exposed to legal claims and regulatory actions arising from the provision of healthcare services, which could materially and adversely affect its reputation, business, financial position, and results of operations.
• The company may experience delays in construction or commencement of operations at new hospitals that it builds, and may be unsuccessful in developing other facilities in the future, which may have an adverse effect on its growth, business, financial condition, results of operations, cash flows and prospects.
• The company is vulnerable to failures of its information technology systems and cybersecurity risks, and any information technology failures including mishandling of medical data could interrupt its operations and adversely affect its reputation, brand, business, financial condition, results of operations, cash flows and prospects.
• The company may require additional capital to support the growth of its business, and this capital might not be available on acceptable terms, if at all.

These are the company's own disclosures, not Alphave's assessment. Read the offer document →

What this page will not tell you

Whether to apply

Alphave is NISM-certified, not a SEBI-registered research analyst. There is no rating, verdict or recommendation on this issue anywhere on this page.

What it will list at

Nobody knows, and GMP is not a forecast of it. It is an unofficial over-the-counter quote reported by third parties, shown here with its source time so you can judge how stale it is.

Your allotment

Allotment is decided by the registrar (KFin Technologies Limited) after the issue closes. Track the whole calendar in the IPO Centre.

← All current and upcoming IPOs · Open the interactive Manipal Health Enterprises terminal →